By Finance Pulse in Stock Market —

Sangamo Stock Falls as Pfizer Ends Hemophilia Collaboration

Sangamo Therapeutics' stock dropped sharply after Pfizer announced it is ending their collaboration on a groundbreaking hemophilia drug. Discover the impact on biotech stocks.

A dynamic and dramatic depiction of a stock market graph plunging, set against the backdrop of a lab
Sangamo Stock Falls as Pfizer Ends Hemophilia Collaboration

Sangamo Therapeutics experiences a significant stock drop as Pfizer ends their collaboration on a hemophilia drug.

Source